Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol vs Ondansetron for PONV Prevention
NCT07087925Completed
- Start
- Jan 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of haloperidol in postoperative nausea and vomiting (PONV) (2 arms). Primary endpoint: Incidence of Postoperative Nausea and Vomiting at 24 hours. Started Jan 2025; status: completed.
02
Drugs
haloperidol
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT07087925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087925.